Journal article
Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites
Abstract
Background: Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneous (sc) formulation approved in 2016 has comparable pharmacokinetics, efficacy, and safety, and a greatly reduced administration time; it is also …
Authors
Stewart DA; Boudreault JS; Maturi B; Boras D; Foley R
Journal
Current Oncology, Vol. 25, No. 5, pp. 300–306
Publisher
MDPI
Publication Date
October 2018
DOI
10.3747/co.25.4231
ISSN
1198-0052